List of Oraverse drug patents
Oraverse is owned by Septodont Holding.
Oraverse contains Phentolamine Mesylate.
Oraverse has a total of 3 drug patents out of which 0 drug patents have expired.
Oraverse was authorised for market use on 09 May, 2008.
Oraverse is available in injectable;injection dosage forms.
Oraverse can be used as a method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic.
The generics of Oraverse are possible to be released after 21 April, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7229630 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jun, 2023
(4 months from now) | |
| US7569230 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Oct, 2023
(8 months from now) | |
| US7575757 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr, 2025
(2 years from now) | |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 09 May, 2008
Treatment: A method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic
Dosage: INJECTABLE;INJECTION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic